We are a clinical-stage biopha      

                                 

OVERVIEW

Pioneering a novel class of therapeutics in Oncology and Immuno-Dysregulated Diseases

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx), which we believe will replace first-line therapies across a multitude of cancer indications.

Press Releases

In January 2023, the 17th new patient was dosed with IMX-110 to datePositive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling […]
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022 in Clinical Cancer Research demonstrated 100% complete response rate; 100% organ response rate; Duration of Response Not Yet Reached at a median follow-up of 5.2 months, […]
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023LOS ANGELES, CA, Dec. 28, 2022 — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced […]